Bristol-Myers Squibb Co Stock Price, News & Analysis

Bristol-Myers Squibb (NYSE:BMY) and its subsidiary Celgene Corporation announced the launch of offers to purchase up to $4 billion in notes. The Offers involve 22 separate series of Notes from 2025 to 2097, with aggregate purchase prices ranging from $500 million to $1.25 billion for each pool. The Offers aim to acquire maximum principal amounts based on priority levels, subject to financing conditions. Early tender premiums of $50 are also included. The Offers will expire on March 15, 2022, with prior deadlines for total consideration eligibility.

Bristol Myers Squibb (BMY) and Exelixis (EXEL) report updated results from the CheckMate -9ER trial at ASCO GU 2022, highlighting the superiority of the Opdivo (nivolumab) and Cabometyx (cabozantinib) combination over sunitinib for advanced renal cell carcinoma. With a median follow-up of 32.9 months, patients receiving the combination achieved a median overall survival of 37.7 months and a progression-free survival of 16.6 months. No new safety concerns were identified, and health-related quality of life was significantly improved in the combination group.

Bristol Myers Squibb (NYSE:BMY) has announced a $5 billion accelerated share repurchase (ASR) program with Morgan Stanley, Barclays, Citibank, and JPMorgan. This repurchase is part of a previously authorized $15 billion multi-year program, leaving approximately $10.2 billion for future buybacks. The ASR transactions are expected to settle in the second and third quarters of 2022, with around 85% of shares repurchased on February 9, 2022. The company plans to finance these transactions with cash on hand, aiming to enhance shareholder value.

Bristol Myers Squibb (NYSE: BMY) announced $7.965 million in health equity grants to 24 U.S. non-profits aimed at improving access to care in underserved communities. This funding is part of a broader commitment of $150 million by 2025 to address health disparities and enhance clinical trial diversity. To date, the total investment towards health equity initiatives has exceeded $39 million. The grants will support community health workers and patient navigators to improve patient care in various therapeutic areas, including oncology and cardiology.

Bristol Myers Squibb (NYSE:BMY) reported Q4 revenues of $12.0 billion, an 8% increase driven by robust sales of Eliquis and immuno-oncology products. Full-year revenues reached $46.4 billion, up 9%. Q4 earnings per share (EPS) stood at $1.07 (GAAP) and $1.83 (non-GAAP), with annual EPS at $3.12 and $7.51 respectively. The company announced a $15 billion share repurchase authorization and provided 2022 guidance, predicting $47 billion in revenues. The outlook includes expected growth from new products and a reduction in operating expenses.

Bristol Myers Squibb (NYSE:BMY) has reported fourth quarter revenues of $12.0 billion, marking an 8% increase year-over-year, and full-year revenues of $46.4 billion. The fourth quarter earnings per share (EPS) stand at $1.07 (GAAP) and $1.83 (non-GAAP), with full-year EPS at $3.12 and $7.51 respectively, reflecting a 17% growth in non-GAAP EPS. The company has authorized a $15 billion share repurchase initiative and announced a $5 billion accelerated share repurchase agreement for Q1 2022. Guidance for 2022 includes projected revenues of approximately $47 billion.

Bristol Myers Squibb (NYSE: BMY) announced that the CHMP of the EMA has recommended the approval of Breyanzi (lisocabtagene maraleucel), a CAR T cell therapy for adult patients with relapsed or refractory aggressive lymphomas. This recommendation follows the successful results of the TRANSCEND NHL 001 trial, the largest pivotal trial for this indication, and the TRANSCEND WORLD study. The final decision from the European Commission is anticipated within 67 days and will affect all EU member states, as well as Iceland, Norway, and Liechtenstein.

BioAtla (Nasdaq: BCAB) announced a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to explore its lead candidates, BA3011 and BA3021, in combination with Opdivo (nivolumab) for solid tumors. BioAtla will sponsor the trials and bear execution costs, while Bristol Myers Squibb will supply Opdivo. Both candidates target AXL and ROR2, which are significant in various cancers, especially after prior anti-PD-1 therapy. This collaboration aims to enhance treatment options for patients with unmet medical needs.

Bristol Myers Squibb (NYSE:BMY) has expanded its collaboration with Arsenal Biosciences to develop next-generation T cell therapies for solid tumors. This follows an option exercise from their December 2020 agreement, which includes undisclosed financial milestone payments. Bristol Myers Squibb will be responsible for the development and commercialization of the new preclinical candidates. The collaboration highlights the potential of ArsenalBio's programmable cell therapy technology, aiming to improve patient outcomes in cancer treatment.